EXELIXIS Being called overvalued by one analyst does not mean that Exelixis (EXEL) is, indeed, overvalued. …

The Week in Review #4 AMAZING STOCK REBOUNDING - We have already witnessed and wrote about …

Mirati Therapeutics (MRTX) announced positive preliminary data from two ongoing clinical trials of its product sitravatinib …

Amicus (FOLD) announced the failure of its topical wound-healing product SD-101 for patients with epidermolysis bullosa …

Marinus Pharmaceuticals’ (MRNS) stock rallied following its announcement of top-line data from Phase 2 open-label study …

In the news, the FDA has placed a clinical hold on two phase 1 trials of …

Coming Soon... The Week in Review #3 Gilead Acquisition - Rallying by Association - Improving on …

Eli Lilly and Company (LLY) and Incyte (INCY) announced that, after discussions with the U.S. Food …

CRISPR Therapeutics (CRSP) and Massachusetts General Hospital Cancer Center (MGHCC) have entered into a two-year research collaboration and license …

The Week in Review #2 The Fairest Upgrades of the Week - Some analysts gave a generous …